{
    "clinical_study": {
        "@rank": "3192", 
        "arm_group": [
            {
                "arm_group_label": "CHR-5154", 
                "arm_group_type": "Experimental", 
                "description": "CHR-5154"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      \u2022 To determine the safety and tolerability of single and multiple ascending oral doses of\n      CHR-5154 in healthy volunteers.\n\n      Secondary Objectives:\n\n        -  To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426.\n\n        -  To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of\n           CHR-5154 in the fed and fasted state."
        }, 
        "brief_title": "Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Arthritis, Rheumatoid", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male volunteers aged 18-45.\n\n          2. Non-smokers from at least three months before receiving the first dose of study drug\n             and for the duration of the study.\n\n          3. Body mass index (BMI) \u2265 18 and \u2264 32 kg/m2.\n\n          4. Body weight \u2265 50 kg and \u2264 120 kg at screening.\n\n          5. Able to voluntarily provide written informed consent to participate in the study.\n\n          6. Must understand the purposes and risks of the study and agree to follow the\n             restrictions and schedule of procedures as defined in the protocol, as confirmed\n             during the informed consent process.\n\n          7. Sexually active male volunteers must use two highly effective methods of\n             contraception with their partners throughout the study and for 90 days after\n             completion of the study.\n\n          8. Male volunteers must not donate sperm during the study and for 90 days after\n             completion of the study.\n\n          9. Must be willing to consent to have data entered into The Over Volunteering Prevention\n             System (TOPS).\n\n         10. The volunteer's primary care physician must confirm that there is nothing in their\n             medical history that would preclude their enrolment into this clinical study\n\n        Exclusion Criteria:\n\n          1. Volunteers with history or presence of significant cardiovascular disease, pulmonary,\n             hepatic, gallbladder or biliary tract, renal, haematologic, gastrointestinal,\n             endocrine, immunologic, dermatologic, neurologic, psychiatric disease or current\n             infection.\n\n          2. Laboratory values at screening or baseline which are deemed to be clinically\n             significant.\n\n          3. QTcF greater than 450 msec at screening.\n\n          4. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.\n\n          5. Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol\n             test at screening or check-in.\n\n          6. Participation in a clinical drug study during the 90 days preceding the initial dose\n             in this study.\n\n          7. Any clinically significant illness within 30 days prior to study drug administration.\n\n          8. Donation of blood or blood products within 90 days prior to study drug\n             administration, or at any time during the study, except as required by this protocol.\n\n          9. Volunteers who have a history or presence of any significant drug allergy.\n\n         10. Use of any prescription or over-the-counter medication (including vitamins, herbal\n             and mineral supplements) within 30 days prior to study drug administration until the\n             end of the study, with the exception of occasional paracetamol approved by the\n             Investigator.\n\n         11. Strenuous exercise, as judged by the Investigator, within 72 hours prior to\n             screening, within 72 hours prior to study drug administration and for the duration of\n             the study until after the post-study medical.\n\n         12. Weekly alcohol intake exceeding the equivalent of 21 units per week.\n\n         13. Consumption of alcoholic beverages within 24 hours prior to study drug administration\n             and during study confinement.\n\n         14. Consumption of caffeine or xanthine-containing products within 24 hours prior to\n             confinement and during study confinement.\n\n         15. Consumption of grapefruit, grapefruit juice, Seville oranges, Seville orange\n             marmalade or other products containing grapefruit or Seville oranges within 7 days\n             prior to confinement and during study confinement.\n\n         16. Volunteers who, in the opinion of the Investigator, are unsuitable for participation\n             in the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934101", 
            "org_study_id": "201302", 
            "secondary_id": "CHR-5154-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "CHR-5154", 
                "description": "CHR-5154", 
                "intervention_name": "CHR-5154", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "contact": {
                "email": "GSKClinicalSupportHD@gsk.com", 
                "last_name": "US GSK Clinical Trials Call Center", 
                "phone": "877-379-3718"
            }, 
            "contact_backup": {
                "email": "GSKClinicalSupportHD@gsk.com", 
                "last_name": "EU GSK Clinical Trials Call Center", 
                "phone": "+44 (0) 20 8990 4466"
            }, 
            "facility": {
                "address": {
                    "city": "Belfast", 
                    "country": "United Kingdom", 
                    "zip": "BT2 7BA"
                }, 
                "name": "GSK Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Double-blind, Randomised, Placebo-controlled, Dose Escalating Study to Assess the Safety and Tolerability of Single and Multiple Oral Doses of CHR-5154 and the Effect of the Fasted and Fed State on Pharmacokinetics of CHR-5154 and CHR-5426 in Healthy Male Volunteers", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of volunteers with adverse events", 
            "safety_issue": "No", 
            "time_frame": "upto 10 days in Single ascending dose phase and 16 days in the Multiple ascending dose phase"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934101"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426.", 
                "safety_issue": "No", 
                "time_frame": "upto 48 hrs post dose"
            }, 
            {
                "measure": "To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.", 
                "safety_issue": "No", 
                "time_frame": "Upto 48 hours"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}